Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company whose news flow centers on the development of TERN-701, a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML). Company updates describe TERN-701 as the lead program in a focused oncology pipeline, with detailed disclosures on clinical data, regulatory interactions and trial design.
News about Terns frequently highlights results from the CARDINAL trial (NCT06163430), a global multicenter Phase 1/2 study of TERN-701 in previously treated chronic phase CML. Press releases and related SEC filings summarize major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability findings, and outcomes in heavily pretreated or difficult-to-treat patient subgroups, including those with prior exposure to other tyrosine kinase inhibitors.
Investors following TERN can also find announcements about regulatory milestones, such as U.S. FDA Fast Track designation for TERN-701 in CML, and information on anticipated clinical priorities and program milestones. Terns’ news includes details on scientific presentations at major conferences like the American Society of Hematology (ASH) Annual Meeting and other healthcare conferences where updated CARDINAL data and development plans are discussed.
In addition, Terns issues news on capital markets activity, including underwritten public offerings of common stock intended to support research, clinical trials, development and manufacturing of key product candidates. Corporate updates may also cover decisions regarding legacy metabolic programs, such as TERN-501, TERN-801 and TERN-601, and the company’s strategy to seek partners for these assets. This news page aggregates such disclosures, offering a centralized view of Terns Pharmaceuticals’ clinical progress, financial developments and strategic focus in oncology.
Terns Pharmaceuticals (Nasdaq: TERN) granted equity inducement awards to two new employees effective February 1, 2026 under its 2022 Employment Inducement Award Plan.
The company approved options to purchase 113,500 shares in aggregate, with a 10-year term, exercise price of $34.60, and standard four‑year vesting subject to continued service.
Terns Pharmaceuticals (Nasdaq: TERN) will present 2026 priorities and program milestones at J.P. Morgan on Jan 12, 2026.
Key points: TERN-701 is in the CARDINAL Phase 1/2 trial with 85+ patients enrolled as of Dec 8, 2025; pivotal dose selection and an End of Phase 2 meeting with the FDA are planned in mid-2026; updated CARDINAL data expected 2H26; initiation of a 2L+ pivotal trial is planned in late 2026/early 2027. TERN-701 received FDA Fast Track designation in Q4 2025. CARDINAL safety and efficacy highlights at ASH: MMR 75% (18/24) by 24 weeks at >320mg QD, DMR 36% (10/28), 87% (55/63) on treatment, grade ≥3 neutropenia 8% and thrombocytopenia 8%. Year-end 2025 cash and marketable securities ≈ $1.0 billion, expected runway into 2031.
Terns Pharmaceuticals (Nasdaq: TERN) announced on January 2, 2026 that it granted inducement equity awards to two new employees under its 2022 Employment Inducement Award Plan.
The company granted options to purchase a total of 312,000 shares of common stock, with a 10-year term and an exercise price of $40.40 per share (the closing price on December 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Terns Pharmaceuticals (Nasdaq: TERN) closed an underwritten public offering on December 11, 2025 of 18,687,500 common shares at $40.00 per share, including 2,437,500 shares sold on exercise of the underwriters' option.
The gross proceeds before underwriting discounts, commissions and expenses were $747.5 million. The company said it will use net proceeds to fund research, clinical trials, development and manufacturing of product candidates including TERN-701, activities preparing for a potential commercial launch of TERN-701, and for working capital and general corporate purposes.
Terns (Nasdaq: TERN) priced an upsized underwritten public offering of 16,250,000 common shares at $40.00 per share, for gross proceeds of approximately $650 million, before underwriting discounts, commissions and expenses.
The company granted underwriters a 30‑day option to purchase up to an additional 2,437,500 shares at the public offering price. The offering is expected to close on December 11, 2025, subject to customary conditions. Net proceeds are intended to fund research, clinical trials, development and manufacturing of product candidates including TERN‑701, initial commercial launch preparations for TERN‑701, and general corporate purposes.
Terns Pharmaceuticals (Nasdaq: TERN) announced a proposed underwritten public offering of $400 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $60 million.
The securities will be offered pursuant to an S-3 shelf registration that became effective on December 9, 2025. Jefferies, TD Cowen and Leerink Partners lead the offering, with Mizuho, Citizens Capital Markets and Oppenheimer & Co. as co-managers.
Terns intends to use net proceeds to fund research, clinical trials, development and manufacturing of key candidates including TERN-701, initial activities for potential commercial launch of TERN-701, and for working capital and general corporate purposes. The offering is subject to market conditions and may not be completed as announced.
Terns (NASDAQ: TERN) reported updated Phase 1 CARDINAL data for TERN-701 at ASH on December 8, 2025. As of a September 13, 2025 cutoff (n=63), 38 efficacy-evaluable patients showed an overall MMR rate of 64% by 24 weeks across all doses and 75% MMR at doses ≥320mg QD. DMR by 24 weeks reached 29% overall and 36% in the ≥320mg cohort. Median treatment duration was six months with a favorable safety profile; Grade ≥3 neutropenia and thrombocytopenia were each 10% (8%). Company hosted an investor webcast on December 8, 2025.
Terns Pharmaceuticals (Nasdaq: TERN) announced that senior management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 4:30 p.m. GMT.
A live webcast will be available on the company's investor relations site at http://ir.ternspharma.com, and a replay will be archived on the site for at least 30 days after the event.
Terns Pharmaceuticals (NASDAQ: TERN) reported third-quarter 2025 results and corporate updates on Nov 10, 2025. Key clinical news: an ASH 2025 abstract and an oral presentation on Dec 8, 2025 will present expanded Phase 1 CARDINAL data for TERN-701, showing a 75% cumulative MMR rate by 24 weeks and 100% MMR durability at cutoff, with encouraging safety across doses. Financial highlights: $295.6M in cash, cash equivalents and marketable securities (Sept 30, 2025), expected runway into 2028. Q3 operating items: R&D $19.9M, G&A $7.8M, net loss $24.6M.
Terns Pharmaceuticals (Nasdaq: TERN) announced equity inducement awards granted to two new employees effective November 1, 2025 under the 2022 Employment Inducement Award Plan.
The company granted options to purchase a total of 252,500 shares of common stock with a 10-year term and an exercise price of $8.26 per share (closing price on October 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).